A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: A randomized, double-masked trial

Journal of Bone and Mineral Metabolism

Volumn 22, Issue 5, 2004, Pages 469-478

  Kushida, Kazuhiro ^a   Fukunaga, Masao ^b   Kishimoto, Hideaki ^c   Shiraki, Masataka ^d   Itabashi, Akira ^e   Inoue, Tetsuro ^f   Kaneda, Kiyoshi ^g   Morii, Hirotoshi ^h   Nawata, Hajime ⁱ   Yamamoto, Kichizo ^j   Ohashi, Yasuo ^k   Orimo, Hajime ^l  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c SAN IN ROSAI HOSPITAL   (Japan)

^d RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f Aoyama General Hospital   (Japan)

^g HOKKAIDO UNIVERSITY   (Japan)

^h OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j TOTTORI UNIVERSITY   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l Tokyo Metropolitan Institute of Gerontology   (Japan)

more..

Author keywords

Bisphosphonate; Etidronate; Fracture prevention; Height loss; Noninferiority; QOL; Risedronate

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; ETIDRONIC ACID; RISEDRONIC ACID;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY HEIGHT; BONE TURNOVER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; INVOLUTIONAL OSTEOPOROSIS; JAPAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINE LEVEL; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL;

AGED; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BODY HEIGHT; BONE AND BONES; COLLAGEN; COLLAGEN TYPE I; ETIDRONIC ACID; FEMALE; HUMANS; INCIDENCE; JAPAN; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; QUALITY OF LIFE; QUESTIONNAIRES; SPINAL FRACTURES;

EID: 4544281893     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-004-0509-z     Document Type: Article

References (25)

1. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344-1352
2. Reginster J-Y, Minne HW, Sørensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
3. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY; Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
4. Cohen S, Levy RM, Keller M (1999) Risedronate therapy prevents corticoid-induced bone loss. Arthritis Rheum 42:2309-2318
5. Reid DM, Hughes RA, Laan RFJM, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15:1006-1013
6. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85:1895-1900
7. Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H; Risedronate Phase III Research Group (2002) A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 13:971-979
8. Ogura Y, Gonsyo A, Cyong J-C, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J Bone Miner Metab 22:120-126
9. Ross PD, Davis JW, Vogel JM, Wasnich RD (1990) A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int 46:149-161
10. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL (1993) Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 8:1227-1233
11. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM (1993) Bone density at various sites for prediction of hip fractures. Lancet 341:72-75
12. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
13. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271
14. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567
15. Storm T, Kollerup G, Thamsborg G, Genant HK, Sorensen OH (1996) Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 23:1560-1564
16. Fujita T, Orimo H, Inoue T (1993) Double-blind multicenter comparative study with alfacalcidol of etidronate disodium (EHDP) in involutional osteoporosis. Clin Eval 21:261-302
17. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139-150
18. Shiraki M, Shiraki Y, Sasaki K, et al. (1997) Clinical research about prevention of a bone fracture in osteoporosis. Osteoporos Jpn 5:533-539
19. Uebelhart D, Gineyts E, Chapuy M-C, Delmas PD (1990) Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 8:87-96
20. Tietz NW, Rinker AD, Shaw LM (1983) IFCC methods for the measurement of catalytic concentration of enzymes. 5. IFCC method for alkaline phosphatase. J Clin Chem Clin Biochem 21:731-748
21. Fukuhara S, Suzukamo Y, Bito S, Kurokawa K (2001) Manual of SF-36, Japanese Version 1.2. Public Health Research Foundation, Tokyo
22. Guideline on clinical evaluation of drugs for osteoporosis. ELD nortification no. 742, April 15, 1999. Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan
23. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trail of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
24. Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2003) A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int 14:225-234
25. Watts NB, Adami S, Chesnut CH (2001) Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 16 (suppl):S407